Kovid, Corp. has been working on a biomedical technology to combat an infectious disease. Kovid estimates the first annual cash flow from this technology to be $500,000, which will be received four years from today. This cash flow will grow at 6 percent thereafter forever. What is this technology worth today if the discount rate is 18 percent